Applying Bioinformatic Tools for Modeling and Modifying Type II <i>E. coli</i> l-Asparginase to Present a Better Therapeutic Agent/Drug for Acute Lymphoblastic Leukemia
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 3
Abstract
Background Asparginase is known to be one of the most important bedrocks of acute lymphoblastic leukemia (ALL) treatment in almost all pediatric regimens in treatment protocols. <i>Escherichia coli</i> L-Asparginase (EC 3.5.1.1) is one of the most common resources to produce this enzyme. One of the affordable methods to overcome the side effects of drug is utilizing bioinformatic tools in the form of In silico study. In this study we designed a new structure of L-Asparginase to decrease its toxicity, reduce some side effects and increase the stability. Methods We used some bioinformatics software and servers like Toxin red, Popmusic, kobami and I-TASSER server to reduce toxicity level of enzyme, and to increase stability and enzyme half-life. Results We obtained 6 protein sequences in which the best was Mut 6 with four changes in structure: L23G, K129L, S263C and R291F. In contrast to the wild type, the new predicted protein is not toxic and has 25 hours more half-life and 600 kcal/mol more stable with no significant change in protein secondary, tertiary structure, antigenicity and allergenicity. Conclusions Finally, sequence number 6 was the only sequence with all distinct characteristics: non-toxic, more stability and more half life.
Authors and Affiliations
Mahdieh Mahboobi, Hamid Sedighian, Mojtaba Hedayati CH, Bijan Bambai, Saeed Esmaeil Soofian, Jafar Amani
Keywords
Related Articles
- EP ID EP237328
- DOI 10.5812/ijcm.5785
- Views 69
- Downloads 0
A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran
Background: Breast carcinoma is not a homogenous disease. It is divided into 5 pathological subtypes of luminal1, luminal2, strongly Her2 positive, basal like, and normal breast like. Basal like breast carcinoma that acc...
Co-Administration of Anti-Angiogenic Peptide and DNA Vaccine in Cervical Cancer Tumor Model
Background Cervical cancer is one of the main causes of women’s death in the world. Human papilloma virus (HPV) types 16 and 18 have been known as a cause of more than 2/3 of cerv...
The Case Report of Laryngeal Adenoid Cystic Carcinoma: A Rare Entity
Introduction: Laryngeal adenoid cystic carcinoma (LACC) is a very rare cancer among laryngopharyngeal malignancies with varieties in presentation. Case Presentation: Here, we discuss a case of 54-year-old female who was...
Comparison of Estrogen, Progesterone and Her2 Receptors in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical Study
Background: Immunohistochemistry (IHC) of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2) are important prognostic factors of breast cancer. However, discordance bet...
Evaluation of Tumor Resectability Rate and Pathologic Response to Preoperative Concurrent Chemoradiotherapy in Locally Advanced Proximal Gastric and Esophagogastric Junction Adenocarcinomas: A Clinical Trial
Background: Preoperative concurrent chemoradiotherapy may improve surgical results and patient survival rates in gastric adenocarcinomas. We aimed to assess tumor resectability and pathologic response rates in patients w...